Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
that may affect its binding strength by modeling the m otion and behavior of
atoms over time.
– Epitope mapping: By pinpointing the areas of the antigen that are essential for
antibody binding, simulations help with epitope mapping. Designing antibodies
with improved specificity for cancer cells while limiting off-target effects is made
possible with the help of this information [112].
– Optimizing binding s: Through the use of molecular simulations, scientists may
methodically investigate changes or alterations in the structure of antibodies. By
enhancing the binding specificity, this procedure helps to guarantee that the ADC
accurately targets cancer cells [113].
17.19.2 Studying payload-release mechanisms
For ADCs to be therapeutically effective, their payload must be released within target
cells in an efficient and controlled manner [114]. Molecular simulations, encompass-
ing MC and MD simulations, offer an insight into the intricate mechanisms that con-
trol payload release.
A crucial component of ADC research is comprehending the complex mechanics
of payload release within target cells, and molecular simulations offer a virtual plat-
form to investigate these mechanisms.
– Linker dynamics: Linker dynamics research is made easier by simulations, par-
ticularly MD [115]. Linkers that enable controlled and efficient payload release
can be designed with the help of researchers who can examine how linkers react
to various physiological situations within a cellular environment.
– Physiological conditions: Molecular simulations shed light on the variables af-
fecting payload release by mimicking how ADCs behave under different intracel-
lular environments, such as pH variations and enzyme activity [116]. The design
of ADCs that release their payload into target cells optimall y is guided by this
knowledge.
– Optimizing linker designs : Because molecular simulations show how various
linker characteristics, including length and flexibility, affect payload release, they
aid in the optimization of linker designs. This information helps with linker cus-
tomization for particular ADC formulations [117].
17.19.3 Understanding ADC stability and pharmacokinetics
The primary factors that determine the effectiveness of ADCs in clinical applications
are their pharmacokinetic characteristics and stability during storage and circulation.
A window into the structural dynamics affecting stability and pharmacokinetics is
provided by molecular simulations [118].
17 Molecular simulation-based technology for antibody–drug conjugates 413
https://t.me/med1917
Molecular simulations can play a critical role in ensuring the stability of ADCs
during storage, circulation, and their pharmacokinetic characteristics.
– Structural dynamics: A glimpse into the structural dynamics of ADC compo-
nents can be obtained by molecular simulations. By examining the structural
changes that payloads, linkers, and antibodies experience over time, researchers
can better understand stability concerns and anticipate possible degradation
pathways.
– Pharmacokinetic profiles: The pharmacokinetic characteristics of ADCs are op-
timized in part through the use of simulations [119]. Researchers can forecast var-
iables affecting clearance rates and tissue-specific accumulation by modeling
their circulation and biodistribution. This knowledge informs the design of ADCs
with the best possible pharmacokinetic characteristics.
– Formulation optimization: The logical design of ADC formulations is aided by
molecular simulations. Simulations help to improve the shelf life and overall sta-
bility of ADCs by guiding the formulation process through an understanding of
the various components’ interactions and influences on stability [120].
Molecular simulations serve as a virtual laboratory for ADC researchers, offering de-
tailed insights into the intricate processes gover ning antibody–antigen interactions,
payload-release mechanisms, and the stability/pharmacokinetics of ADCs [121]. These
computational techniques, complemented by experimental data, contribute to the ra-
tional design and optimization of ADCs, ultimately enhancing their efficacy and trans-
lational potential in cancer therapy.
17.20 ADC design is informed by case studies
and success stories in molecular simulations
The success of ADCs in cancer therapy can be attributed in large part to the crucial
role those molecular simulations played in directing the design of these drugs. In this
case, we illustrate particular instances where molecular simulations have been useful
in guiding the design of ADCs to achieve higher specificity and efficacy [122].
17.20.1 Examples of molecular simulations guiding ADC design
17.20.1.1 Trastuzumab emtansine (T-DM1)
An ADC with FDA approval, T-DM1 is used to treat HER2-positive breast cancer.
To forecast the dynamic interactions between the trastuzumab antibody and the
HER2 antigen, molecular simulations were utilized. Researchers refined the antibody
414 Abhishek Singh et al.
https://t.me/med1917
for improved selectivity and binding affinity to HER2-expressing cancer cells by
modeling various conformations and binding scenarios. As a result, T-DM1’s design
was more logically created, improving therapeutic efficacy [123].
17.20.1.2 Brentuximab vedotin (Adcetris)
An ADC called Adcetris is used to treat systemic anaplastic large cell lymphoma and
Hodgkin’s lymphoma.
Using MD simulations, the behavior of the linker-payload complex under differ-
ent physiological circumstances was investigated. The ideal linker characteristics
needed for regulated payload release into cancer cells were identified by the simula-
tions [124]. The stability and effectiveness of Adcetris were enhanced by the choice of
a suitable linker, which was led by the insights obtained from simulations.
17.20.1.3 Glembatumumab vedotin (CDX-011)
An ADC called CDX-011 was created to treat breast cancer and metastatic melanoma.
Molecular simulations were utilized by researchers to forecast the conforma-
tional alterations that the CDX-011 complex will undergo upon binding to its intended
antigen. The antibody was modified to improve binding selectivity and lessen off-
target effects based on this finding. The ADC design was optimized for better tumor
targeting thanks in large part to the simulations [125].
17.20.2 Improving stability and efficacy through simulations
17.20.2.1 Case study: stability enhancement of an ADC linker
An ADC experienced storage-related stability problems that resulted in early linker
cleavage and decreased efficacy.
MD simulations were utilized to examine the behavior of the linker at various
temperatures and solvent conditions [126]. The linker’s structural dynamics were re-
vealed by the simulations, highlighting potential instability-causing weaknesses.
To improve stability, researchers changed the linker structure based on simula-
tion data. Molecular simulations guided the optimized linker design, which greatly ex-
tended the ADC’s shelf life while preserving its structural integrity, increasing its
therapeutic efficacy.
17 Molecular simulation-based technology for antibody–drug conjugates 415
https://t.me/med1917
17.20.3 Case study: pharmacokinetic optimization of an ADC
An ADC’s circulation time and biodistribution were impacted by its subpar pharma
cokinetics.
To anticipate clearance rates and model the biodistribution of the ADC in various
organs, pharmacokinetic simulations were performed. Understanding how the pay-
load, linker, and antibody components affected pharmacokinetic parameters was
made possible by molecular simulations [127].
In order to enhance the pharmacokinetic profile of the ADC, researchers adjusted
the formulation with the help of simulation findings. Longer circulation, more tumor
accumulation, and less nonspecific clearance were the effects of the improved design,
all of which improved therapeutic outcomes.
17.21 Future directions and emerging technologies
in molecular simulations for ADCs
Current advancements in high-performance computing (HPC) and artificial intelligence
(AI) are being incorporated into the dynamic area of molecular simulations for ADCs
[128]. The breadth, precision, and effectiveness of the molecular simulations utilized in
ADC design and optimization could be greatly enhanced by these advancements.
17.21.1 Integration of artificial intelligence
17.21.1.1 Machine learning for enhanced sampling
To discuss difficulties in reaching convergence and investigating uncommon occur-
rences in molecular simulations, algorithms for machine learn ing are combined to
improve sample plans. These methods accelerate the study of intricate energy land-
scapes by using simulation data to identify advantageous moves in configuration
space [129] and increase exploration efficiency in conformational spaces, allowing
simulations to catch uncommon occurrences and transitions that were computation-
ally difficult to record with conventional techniques.
17.21.1.2 Predictive models for binding affinities
To streamline the process of predicting antibody–antigen binding affinities and opti-
mizing ADC designs, machine learning models, trained on diverse datasets of anti-
416 Abhishek Singh et al.
https://t.me/med1917
body–antigen interactions and their corresponding binding affinities, are used to pre-
dict binding strengths based on structural features.
Rapid and accurate predictions of binding affinities, aiding in the selection and
optimization of antibodies for ADCs [130] accelerate the early stages of ADC develop-
ment and reduce the need for extensive experimental screening.
17.21.1.3 AI-driven optimization of linker properties
To enhance the stability and controlled payload release of ADCs through informed
linker design, AI algorithms analyze simulation data to identify optimal linker proper-
ties, considering factors such as flexibility, cleavability, and stability under different
conditions.
AI-driven insights contribute to the rational design of linkers, improving the over-
all stability of ADCs during storage and circulation, and ensuring controlled payload
release within target cells [131].
17.21.2 High-performance computing advancements
17.21.2.1 Parallelization for large-scale simulations
To overcome computational bottlenecks and enable simulations of larger and more
complex systems, MD simulations are parallelized across multiple processors or GPUs,
allowing for the simultaneous computation of different trajectories [132].
Accelerated simulations of large ADC systems facilitate the study of interactions
at a more detailed level, enabling investigations into the behavior of heterogeneous
tumor environments.
17.21.2.2 Quantum computing for quantum mechanical simulations
To investigate quantum events and electronic structure, two aspects of quantum me-
chanics that influence ADC behavior are:
1. utilizing the powers of quantum computing to run simulations, based on quan-
tum physics, allowing for more precise depictions of electrical interactions [133].
2. increased precision in forecasting electronic characteristics and interactions, pro-
viding a deeper comprehension of the quantum factors impacting ADC behavior.
17 Molecular simulation-based technology for antibody–drug conjugates 417
https://t.me/med1917
17.21.3 Advanced sampling techniques
To enhance the exploration of conformational spaces and improve the accuracy of
molecular simulations, implementation of advanced sampling techniques, such as
metadynamics and replica exchange MD, help to overcome energy barriers and ex-
plore rare events. Improved sampling of relevant conformations lead to more accu-
rate predictions of ADC behavior under varying conditions [134].
The integration of state-of-the-art technologies is demonstrated by these current
advances in molecular simulations for ADCs, pointing to a future when simulations
will not only be more effective but will also be able to capture intricate and subtle
elements of ADC behavior [135]. The combination of HPC and AI has the potential to
completely transform the sector by providing new insights and speeding up the crea-
tion of more potent ADCs for cancer treatment.
17.21.4 Challenges and opportunities in ADC development
17.21.4.1 Unexplored aspects in ADC development: intracellular dynamics
and payload release
Comprehending the complexities of payload release in the diverse and ever-changing
intracellular milieu continues to be a formidable obstacle.
By better mimicking intracellular variables, including pH fluctuations and en-
zyme activity, advances in molecular simulations can shed light on the kinetics of pay-
load release [136]. A more thorough knowledge of the chemical reactions involved
might be possible by including simulations of quantum mechanics.
17.21.4.2 Patient-specific responses
One problem facing customized medicine is the variability in patient responses to ADCs,
which can be attributed to various factors such as genetics and tumor heterogeneity.
Personalized ADC design is made possible by fusing patient-specific data – such
as genetics and tumor profiling – with molecular simulations. Customized ADC formu-
lations can be developed with the help of AI-driven simulations that can anticipate
unique reactions [137].
17.21.4.3 Immunogenicity and antibody engineering
Immunogenic responses to ADCs, particularly involving nonhuman antibodies, pres-
ent challenges in terms of safety and efficacy.
418 Abhishek Singh et al.
https://t.me/med1917
Molecular simulations can model immune responses to ADC components, aiding
in the identification of potential immunogenic epitopes [138]. This information in-
forms antibody engineering strategies to reduce immunogenicity, enhancing overall
safety.
17.21.4.4 Multivalent targeting and combination therapies
There are several intricate design concerns when investigating the possibilities of
multivalent targeting and combination therapy with ADCs.
Molecular simulations can be used to evaluate the effects of combination therapy
and model how ADCs interact with various targets. These simulations offer valuable
perspectives on how to optimize multivalent designs to improve therapeutic ef-
fects [139].
17.21.4.5 Long-term stability and aggregation
Translational success depends on ADC stability being maintained over long times, par-
ticularly during storage.
Molecular simulations evaluate possible aggregation pathways and structural dy-
namics to forecast the long-term stability of ADC formulations. This helps to optimize
formulation tactics and storage conditions [140].
17.21.5 Opportunities for interdisciplinary collaborations
17.21.5.1 Combining experimental and computational approaches
A synergistic approach is made possible through collaboration between computa-
tional scientists and experimentalists. While simulations direct and interpret experi-
ments, generating a thorough understanding of ADC behavior, the integration of
experimental data into simulations validates and improves models [141].
17.21.5.2 Interdisciplinary training programs
Creating training programs that facilitate knowledge transfer between experimental
and computational fields helps to produce a new breed of researchers who can com-
bine both methods with ease. This multidisciplinary knowledge is essential for han-
dling the complex issues in ADC development.
17 Molecular simulation-based technology for antibody–drug conjugates 419
https://t.me/med1917
17.21.5.3 Pharmacology and systems biology integration
Computational modelers, systems biologists, and pharmacologists working together
can produce complete models that take the systemic effects of ADCs into account
[142]. A comprehensive understanding of pharmacokinetics, pharmacodynamics, and
total therapeutic responses is offered by this method.
17.21.5.4 Cross-sector collaborations
Partnerships among academic institutions, pharmaceutical firms, and regulatory
agencies can expedite the conversion of computational discoveries into useful applica-
tions. When it comes to directing the development of ADCs, pooled resources and
knowledge improve the computational models’ resilience and relevance.
17.21.5.5 Patient advocacy and ethical considerations
An approach that is patient-centric is ensured when interdisciplinary teams include
ethicists and patient advocacy groups [143]. For the development of ADCs to be ethi-
cally sound and transparent, it is essential to comprehend patient viewpoints and
take ethical issues into account.
The opportunities provided by interdisciplinary collaborations can help address
the challenges posed by the undiscovered parts of ADC development. Through the in-
tegration of experimental and computational methodologies and the establishment of
cross-disciplinary collaborations, scientists can uncover novel perspectives, surmount
obstacles, and establish novel and efficacious anti-cancer drugs [144].
17.22 Regulatory landscape for ADC development
Health agencies, including the European Medicines Agency (EMA) and the US FDA,
oversee the regulatory environment for ADCs [145]. These organizations offer policies
and procedures to guarantee the se curity, effectiveness, and caliber of ADCs during
the course of their creation and authorization.
420 Abhishek Singh et al.
https://t.me/med1917
17.22.1 FDA and EMA guidelines for ADC development
17.22.1.1 FDA guidelines
– The US FDA offers guidelines for the creation of ADCs in the form of documents
like “Guidance for Industry: Antibody–Drug Conjugates for the Treatment of Un-
resectable Solid Tumors.”
– Manufacturing, clinical trial design, preclinical research, and regulatory submis-
sion tactics are important factors to take into account. The FDA stresses how cru-
cial it is to comprehend biological systems, define essential quality qualities, and
guarantee the efficacy and safety of products [146].
17.22.1.2 EMA guidelines
– ADC development guidelines are provided by the EMA, which also publishes the
“Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical
Trials with Investigational Medicinal Products.”
– Comprehensive nonclinical assessments, risk reduction techniques, and early in-
teraction with regulatory bodies are all emphasized in EMA guidelines [147]. They
emphasize that moving ADCs from preclinical development to clinical trials re-
quires a methodical strategy.
17.22.2 Ethical considerations in molecular simulations
17.22.2.1 Ensuring accuracy and reliability
Transparent methodology and validation
– Methodology transparency is necessary for ethical practice in molecular simula-
tions. Simulation circumstances, force field characteristics, and any changes to
conventional processes must all be explicitly stated in research protocols.
– To guarantee the accuracy of simulations, validation against experimental data is
essential. It is imperative to explicitly articulate the constraints of simulations
and resolve disparities between the outcomes of experiments and simulations
Responsible use of AI and machine learning
– When integrating AI and machine learning in simulations, ethical considerations
include ensuring fairness, transparency, and accountability. Models should be
trained on diverse and representative datasets to avoid biases [148].
17 Molecular simulation-based technology for antibody–drug conjugates 421
https://t.me/med1917
– Rigorous validation and benchmarking of AI-driven simulations against known
experimental outcomes are necessary to establish their reliability and prevent
unintended consequences.
17.22.3 Transparency and reproducibility
17.22.3.1 Open science practices
– Ethical molecular simulations necessitate implementing open science methodolo-
gies. Openly sharing simulation protocols, code, and datasets is one way to pro-
mote reproducibility and transparency.
– The reproducibility of findings is increased when simulation results are transpar-
ently reported, together with statistical analysis and uncertainties [149]. This also
enables other researchers to check or expand on the study.
17.22.3.2 Data sharing and collaboration
– Collaborative efforts and data sharing within the scientific community contribute
to ethical practices [150]. Sharing simulation data, especially negative results or
challenges encountered, enhances collective knowledge and prevents redundant
efforts.
– Establishing community standards for rep orting simulation methodologies and
results promotes consistency and facilitates the ethical advancement of the field.
17.22.3.3 Ethical review and oversight
– Institutional review boards (IRBs) and ethical oversight committees play a role in
ensuring that molecular simulations involving human data or sensitive informa-
tion adhere to ethical standards.
– Researchers should seek ethical review for studies involving patient-specific data,
and informed consent should be obtained when applicable [151].
17.22.3.4 Adherence to standards and guidelines
Ethical behavior is ensured by adhering to set norms and regulations, such as those
provided by consortiums or professional organizations. This entails abiding with the
ethical standards of the scientific community as well as simulated reporting criteria.
422 Abhishek Singh et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана